ClinicalTrials.Veeva

Menu
D

DENT Neurologic Institute | Headache, Concussion, and Neuro-oncology Research

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

LY3841136
Sumatriptan
LY3305677
Lamotrigine
Galcanezumab
Dexamethasone
ABP-450
Simufilam
PF-06649751
Naprosyn

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

18 of 68 total trials

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various...

Enrolling
Overweight
Obesity
Drug: LY3305677
Drug: LY3549492

Prospective, multi-center, double blind, randomized, sham-controlled study to evaluate neuromodulation in patient with chronic migraine. The study hy...

Enrolling
Headache Migraine Chronic
Device: Neurostimulator

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.Additional part...

Active, not recruiting
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participant...

Enrolling
Chronic Migraine
Drug: Placebo
Drug: Galcanezumab

The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatme...

Enrolling
Episodic Migraine
Drug: Galcanezumab
Drug: Placebo

The main purpose of this study, performed under a master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safety...

Active, not recruiting
Overweight and Obesity
Obesity
Drug: Placebo
Drug: LY3305677

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safet...

Active, not recruiting
Overweight and Obesity
Obesity
Drug: Placebo
Drug: LY3841136

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to evaluate the effects of LY3549492 in adults with...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: LY3549492

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136...

Enrolling
Overweight
Obesity
Drug: Placebo
Drug: LY3841136

In this study, researchers will learn more about a study drug called BIIB080. The study will focus on participants with mild cognitive impairment or...

Active, not recruiting
Mild Cognitive Impairment Due to Alzheimer's Disease
Alzheimer's Disease Dementia
Drug: BIIB080-matching placebo
Drug: BIIB080

This is a master protocol for 3 independent, seamlessly enrolling, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies...

Enrolling
Alzheimer's Disease Psychosis
Drug: Placebo
Drug: ACP-204

The objectives of the trial are to evaluate the long-term efficacy and safety of HORIZANT (Gabapentin Enacarbil) 600 mg daily, for the treatment of R...

Enrolling
RLS
Drug: HORIZANT 600 mg

The goal of this clinical trial is to is to test whether Walkasins can help people with peripheral neuropathy maintain their balance better. The main...

Not yet enrolling
Balance Control in Elderly
Peripheral Neuropathy With Type 2 Diabetes
Other: Fall Prevention Training
Device: Walkasins

This is a Phase IIb study to evaluate the safety and preliminary efficacy of Descartes-08 CAR T-cells in patients with Generalized Myasthenia Gravis

Enrolling
Myasthenia Gravis, Generalized
Drug: Descartes-08

The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the dis...

Enrolling
Multiple Sclerosis
Drug: Frexalimab
Drug: Placebo
Recently updated

This study will be conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetics of masupirdine compared to placebo for the treatmen...

Enrolling
Agitation
Alzheimer's Type Dementia
Drug: Masupirdine 100 mg
Drug: Placebo

This is a multicenter, longitudinal, single-arm, open-label study to describe the change from baseline in cognitive processing speed, measured by the...

Active, not recruiting
Multiple Sclerosis
Drug: RPC-1063

This is a randomized, double-blind study of PIPE-307 or placebo in subjects with relapsing-remitting multiple sclerosis. Subjects will be randomized...

Active, not recruiting
Relapsing Remitting Multiple Sclerosis
Drug: Placebo
Drug: PIPE-307 Dose A

Trial sponsors

Lilly logo
D
C
A
Allergan logo
A
Biogen logo
C
C
E

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems